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IP001 
THE BONE AND JOINT DECADE: IMPACT OF 
OSTEOARTHRITIS 
D. P. M Symmons 
ARC Epidemiology Unit, University of Manchester, UK 
In January 2000, the World Health Organisation endorsed the ten 
years beginning in the year 2000 as the 'Bone and Joint Decade'. 
One of the first activities of the Decade was a workshop which 
focused on estimating "the global burden of musculoskeletal con- 
ditions. Five index conditions were selected: rheumatoid arthritis, 
osteoarthritis (OA), osteoporosis, spinal disorders and major limb 
trauma. 
It is acknowledged that OA is probably the predominant cause of 
joint-related morbidity in all populations. Projections based on the 
1990 Global Burden of Disease project suggest that knee OA is 
likely to become the 4th most important cause of disability in 
women and the 8th most important cause in men in more devel- 
oped countries within the next decade. This is mainly as a 
consequence of the ageing population, but also because some of 
the risk factors for knee OA, in particular obesity, are becoming 
more prevalent. The number of people with hip OA will also 
increase as a consequence of the ageing population although the 
age and gender specific prevalence appears to be stable. The 
greatest numbers of cases of OA will be in China. 
The burden of OA can be measured in a number of ways. At 
present most data relate to pain and physical disability. New tools 
are needed to explore the cumulative lifetime impact of OA from 
the time of first symptoms. Data are also needed on the psycho- 
logical and socio-economic onsequences of OA, especially in less 
developed countries. 
The Bone and Joint Decade focuses on the burden of OA for the 
individual and for society. Society may bear both the direct costs of 
the healthcare provision and the indirect costs of loss of economic 
activity. Until the advent of effective secondary preventive 
measures, the need for major replacement surgery (and for 
orthopaedic surgeons) will rise year on year. The changing age- 
structure of the population will also impact on the way that 
healthcare can be funded. Healthcare costs will rise while a lower 
percentage of the population will be in the working age group. 
The monitoring of targets for improved recognition and treatment 
of OA requires data on the occurrence and outcome of the disease. 
There are many parts of the world, in particular in South America 
and Africa, for which there are no data and this needs to be 
rectified. 
IP002  
IMAGING OSTEOARTHRITIS 
lain Watt 
Department of Clinical Radiology, Bristol Royal Infirmary, Bristol, 
UK 
Osteoarthritis, one disease or many?: Radiological imaging 
demonstrates a series of subsets of OA distinct from the normal 
processes involved in ageing. These include hypertrophic OA 
(often associated with CPPD crystals), atrophic (usually with BCP 
crystals), erosive (a radiological, hand subset), elbow (male, 
middle aged) and reparative (e.g. 'secondary' to an old inflam- 
matory arthropathy). Thus, imaging details structural abnormality, 
monitors change, assesses deformity and reduced functional 
capacity as well as distinguishing between disease distribution 
subsets, secondary (or primary?) bone responses and disease 
activity. 
Understanding the pathophysio logy:  Radiology has shown 
that OA comprises a phasic series of processes. These can be 
documented individually but may be out of sequence with each 
other. For example whilst long term follow up, using plain X-ray 
films, documents change over time, such change is slow, affects 
only a small proportion of patients and correlates poorly with 
clinical findings. However, scintigraphy, using bone-seeking 
agents, demonstrates those joints that are biologically active and 
has proven of predictive value of subsequent X-ray change in 
population studies. Further, it has identified specific subsets of 
disease process within knee OA, possibly with different prognostic 
significance. Scintigraphic changes correlate with venous markers 
and types of osteophyte shown on MRI. Scintigraphy forces a 
reappraisal of whether OA is a cartilage or bone disease, or both. 
Studies of trabecular organisation using microfocal techniques 
suggest fundamentally different processes are involved that result 
in sclerotic bone and osteophytosis. DEXA scanning has been 
applied also to knee OA, revealing intriguing changes that corre- 
late also with scintigraphic findings. MRI now routinely extrapolates 
cartilage volume, but can also show dynamic changes, for 
example secondary to joint loading. Long term MRI studies are 
now available showing the development and resolution of hyaline 
cartilage pathology in OA. Further, experimental pulse sequences 
demonstrate early hydration changes, and may allow direct 
imaging of proteoglycan concentration. 
Conclusion: Imaging has a crucial role in clinical studies of OA, 
both by defining subsets and understanding underlying processes. 
In future, it will be possible not only to identify structural change, 
but also to monitor pathological and repair processes in hyaline 
cartilage and subchondral bone. Thereby distinction will be made 
between changes related to simple ageing, those with a poor 
outcome and possibly treated, and those to be encouraged as 
repair. 
I P003  
MOLECULAR MARKERS IN OSTEOARTNRITIS 
D. He!neg&_rd, P. Lorenzo, B. M&nsson and T. Saxne 
Depts of Cell & Mo/ecu/ar Bio/ogy and Rheumato/ogy, Lund 
University, Lund, Sweden 
The early events in the process of developing cartilage destruction 
and bone involvement in osteoarthritis are poorly known. The 
earliest event that can be detected macroscopically appears to be 
swelling and some surface fibrillation of the cartilage. It is not 
known whether such alterations necessarily progress to the 
"advanced tissue changes seen in osteoarthritis. It is however 
important to keep in mind that already the early macroscopical 
changes represent a partial failure of the molecular organization of 
the articular cartilage. Therefore, to further our knowledge on these 
events we do need new procedures for their detection. Such 
approaches are likely to focus on the molecules that represent the 
building blocks of the matrix. Normally these molecules are 
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retained in the tissue, being part of its macromolecular organiza- 
tion. In processes requiring modifications of the tissue structure 
due to damage and/or altered mechanical requirements, the cells 
will respond by removal of some matrix constituents and produc- 
tion of new ones to accomplish build-up. Thus, degradation yields 
fragments that are not retained in the tissue and diffuse away such 
that they may be detected in surrounding fluids and eventually 
serum. As a result of an increased synthesis other molecules may 
be produced in excess and escape incorporation in tissue 
structures and be free to diffuse into the surrounding where they 
may be detected. An increasing number of cartilage matrix con- 
stituents have been identified and assays for their quantification 
have been developed. Studies of altered release of cartilage matrix 
constituents in joint disease have shown their potential for identi- 
fying individuals with an active disease process. Thus, one such 
component is COMP that appears to be a sensitive indicator of 
ongoing processes and correlate to outcome measures like 
developing joint space narrowing. 
In evaluating studies of such markers, it needs to be stressed that 
an increased level of a particular molecular fragment in a tissue 
fluid sample is a consequence of an ongoing process in the tissue 
where the molecule originates. This contrasts to images by X-ray 
or MRI showing decreased cartilage height. This is a consequence 
of events that have happened prior to the image being recorded 
and provides no information on whether there is an active process. 
Molecular marker analyses will provide new opportunities to 
monitor the activity of the process leading to tissue destruction and 
their use in identifying patients with an active process amenable to 
therapeutic intervention as well as monitoring the efficacy of the 
intervention. 
IP004 
MONITORING OSTEOARTHRITIS PROGRESSION AND 
THERAPY 
Maxime Dougados 
Rene Descartes University, AP-HP Cochin Hospital, 75014 Paris, 
France 
Background: Different international societies have recently 
proposed recommendations for evaluating both the symptomatic 
and structural effects of drugs in osteoarthritis. Most of the tools 
evaluating these domains are continuous variables. Usually, 
clinical trials report the average improvement experienced by 
treated patients. The presentation of the results on an individual 
basis (i.e,, responder yes/no) offer a lot of advantages including an 
easier understanding by clinicians. Some of these recommenda- 
tions can be easily applied in daily practice. Moreover, the 
presence of symptoms suggestive of an inflammatory episode of 
OA should be systematically checked at each visit, 
Symptomatic severity of osteoarthritis: Three domains 
evaluating the symptomatic severity of osteoarthritis have been 
selected by different societies, i.e., pain, functional impairment and 
patient's global assessment. For each individua/ too/ (e.g. pain 
VAS, WOMAC pain, WOMAC function, etc.) a cut-off in the 
changes of the variables can define an improvement. This cut-off 
can be selected based either on the definition of the Smallest 
Detectable Difference (SDD) or Minimum Individual Difference 
(MID) or based on the definition of the Minimum Clinically Import- 
ant Difference (MCID). For this last approach, the patient's per- 
spective is important o consider. A composite index taking into 
account the 3 main domains has been recently proposed by the 
OARSI Task Force for Clinical Trials. This preliminary OARSI 
Responder Criteria can be applied in patients with hip or knee 
osteoarthritis. Moreover, in daily practice, the presence of one or 
more of the following: sudden increase in pain, night pain, morning 
stiffness, hydarthrodial effusion is very suggestive of an inflamma- 
tory episode of the disease and might indicate specific therapies. 
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Structural severity of osteoarthritis: Most of the tools permit- 
ting to evaluate the severity of chondropathy (e.g. radiological joint 
space width, arthroscopical evaluation, etc.) are also continuous 
variables. Here again, a cut-off in the changes in these variables 
can define a progression. The Smallest Detectable Difference can 
be defined based on the measurement error (reliability of the 
technique). Minimum Clinically Important Difference is more 
difficult o define. The evaluation of the predictive validity has been 
proposed for such purpose. For example, a longitudinal study of 5 
year duration of more than 500 hip OA patients has suggested that 
a change of at least 25% during one year in the radiological joint 
space width is highly predictive of a subsequent requirement for 
Total Hip Replacement. 
Conclusion: The presentation of the results of clinical studies in 
OA on an individual basis is very relevant and necessitate a large 
international consensual approach permitting to uniformize and 
facilitate the medical language. These tools together with the ones 
permitting to check the presence of an inflammatory episode of the 
disease are also useful in daily practice. 
IP005 
SUBCHONDRAL BONE AND OSTEOARTHROSlS 
D. B. Burr 
Indiana University School of Medicine, Indianapolis, IN, USA 
The positive association between subchondral bone sclerosis and 
OA has been known for some time, but the etiologic role that bone 
plays in the degenerative process is still not clear. Evidence 
suggests that patients with OA have 5-15% greater BMD and 30% 
greater bone volume than the non-OA population. This is 
accompanied by architectural changes in the trabeculae that 
reduce complexity of the trabecular network. These changes are 
distinct from those that occur during aging. The apparent density of 
subchondral bone is increased because of the increased 
trabecular volume and thicker subchondral plate, even though the 
material density is decreased in OA subjects because the bone is 
hypomineralized. The greater apparent density, however, 
increases bone stiffness and impairs the bone's ability to act as a 
shock absorber. Thus, in OA, increased bone turnover reduces 
material density and material stiffness, but increased thickness of 
bone is associated with a higher structural modulus. There is some 
evidence that the composition of the bone, apart from its mineral- 
ization, also may be different in subjects with OA, leading some to 
speculate that OA is part of a generalized metabolic bone disease 
in which there is a defect that leads to the formation of poor quality 
bone. Higher IGF-I, IGF-II and TGF-~ levels have been identified in 
matrix from the lilac crest in OA subjects. Both IL-6 and IL-11 are 
less abundant in bone from OA subjects, whereas osteocalcin 
mRNA is more highly expressed. Moreover, some have shown an 
altered osteoblast phenotype with in(;reased cellular release of 
IGF-I and urokinase plasminogen activator. These observations 
suggest that there may be differences in bone composition or 
cellular activity in OA that can contribute to or are associated with 
the underlying degenerative disease. However, other studies show 
no differences in IL-lJ3, TGF-~, bFGF, IL-6 or TNF-o~. The idea that 
OA is a generalized bone disease also is disputed by data that 
bone density is not increased at all sites in people with OA. The 
evidence that bone apparent density and structural stiffness are 
elevated in OA appears incontrovertible, although the temporal 
sequence of these events is still debatable. Currently, OA is best 
considered a disease of unknown origin in which both bone and 
cartilage are changed in ways that indicate a positive feedback 
between them in the degenerative process. 
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IP006 
INFLAMMATION IN OSTEOARTHRITIS 
J.-P. Pelletier, J. MarteI-Pelletier, D. Lajeunesse, D. V. Jovanovic, 
P• Reboul and J. Fernandes 
Osteoarthritis Research Unit, Centre hospitalier de I'Universite de 
Montreal, Montreal, Quebec, Canada 
Mainly due to recent progress in the understanding of its patho- 
physiology, several interesting advances toward {he treatment of 
osteoarthritis (OA) have been made. OA can be described as the 
degradation and loss of articular cartilage, accompanied by 
subchondral bone remodeling, osteophyte formation and synovial 
membrane inflammation. 
There is now evidence that the initiation and progression of OA is 
complex. I will discuss the different mechanisms believed respon- 
sible for the progression of OA. The structural changes in cartilage 
are thought to be related to a network of biochemical factors, 
including proteases from the metalloprotease family. Furthermore, 
proinflammatory cytokines such as IL-11~ also contribute to these 
changes. A relative deficit in the production of the antagonist of IL-1 
receptors, IL-1Ra, coupled with an upregulation of the receptor 
level, are additional factors enhancing the catabolic effect of IL-1 l} 
in OA. This cytokine not only favors tissue destruction but also 
inhibits tissue repair. OA also involves changes in the surrounding 
bone. It is now recognized that subchondral bone sclerosis is an 
important manifestation in human OA. I will depict data showing 
that proinflammatory cytokines are involved in the metabolism of 
OA abnormal subchondral bone osteoblasts. 
A better understanding of the mechanisms of joint damage has led 
to the development of a new class of molecules for their potential 
to alter the degenerative process. A number of biological agents 
that suppress proinflammatory cytokine activity, such as IL-1Ra, 
cytokine soluble receptors and anti-inflammatory cytokines, have 
demonstrated potentially beneficial therapeutic properties. Studies 
have also shown that the excess production of nitric oxide (NO) in 
OA cartilage is injurious, and might be related to an increased level 
of proinflammatory cytokines in this tissue. Moreover, data also 
indicates that chondrocyte apoptosis is likely to contribute to the 
OA process. These phenomena are related to the excess produc- 
tion of inflammatory mediators such as NO, PGE 2 and also 
possibly LTB 4. 
The current understanding of the factors involved in this disease 
has evolved greatly. Improved comprehension of the modulating 
factors as well as the major regulators has shown that pro- 
inflammatory cytokines are effective targets with therapeutic 
potential in OA treatment. 
IP007  
CARTILAGE AGING AND THE DEVELOPMENT OF 
OSTEOARTHRITIS 
R. F. Loeser, C. S. Carlson and G. Shanker 
Rush Medical College of Rush-Presbyterian-St. Luke's Medical 
Center, Chicago, IL., and the Univ. of Minnesota, St. Paul MN, 
USA 
The development of osteoarthritis (OA) is closely associated with 
aging but the exact role of aging in the pathogenesis of OA is not 
clear. Aging-related changes have been noted in the structure 
and/or function of bone, cartilage, muscle, ligaments, and other 
soft tissues of the joint which could contribute to the development 
of OA• The age-related changes observed in cartilage include a 
decrease in the proliferative and synthetic capacity of chondro- 
cytes, increased cell death, and alterations in extracellular matrix 
molecules including collagens and proteoglycans. We have 
studied the development of naturally occurring OA in non-human 
primates as a model of the human disease. Like human OA, the 
pathologic changes observed in cartilage are age-related and are 
accompanied by changes in the subchondral bone. Studies of 
monkey chondrocytes isolated from knee cartilage have revealed 
an age-related decline in the ability to respond synthetically to 
stimulation with IGF-I• The reduced response appears to be 
secondary to defective IGF-I receptor-mediated cell signaling• 
There is also a reduced IGF-I response in cells from OA cartilage 
but the mechanism appears to differ from aging. These studies 
serve to emphasize that aging and OA are not one and the same. 
Because chondrocytes from histologically normal cartilage of old 
monkeys demonstrate a reduced IGF-I response, factors in 
addition to an age-related loss of growth factor response are 
necessary for OA to develop. Increased production of IL-1 is 
observed in OA cartilage but not normal cartilage of older monkeys 
consistent with the theory that an imbalance in anabolic and 
catabolic factors results in OA. In cell culture studies of monkey 
and human articular chondrocytes, we have found that in addition 
to its ability to stimulate synthesis of matrix proteins, IGF-I serves 
as a key survival factor for chondrocytes. Reduced survival 
signaling with age is another potential mechanism by which aging 
cartilage would be more susceptible to the development of OA. 
Together, the observed age-related changes would appear to 
make cartilage more subsceptible to damage and less able to 
repair damage once it occurs but factors in addition to aging alone 
are necessary to produce OA. 
IP008  
CLINICAL TRIALS: IMPACT OF INTRA-ARTICULAR STEROID 
INJECTIONS ON THE PROGRESSION OF KNEE 
OSTEOARTHRITIS 
J.-R Raynauld, C. Buckland-Wright °. J.-L. Tremblay, V. Khy, 
C. Bertrand, D. Choquette, B~ Haraoui, J. MarteI-Pelletier and 
J.-P. Pelletier 
Osteoarthritis Research Unit, Centre hospita/ier de/'Universite de 
Montreal, Montreal, Quebec, Canada, and *Guy's and St. Thomas 
Hospitals, London, England 
Knee osteoarthritis (OA) is a disease characterized mainly by 
cartilage degradation, clinically reflected by a gradual development 
of joint pain, stiffness and loss of motion. Intra-articular cortico- 
steroid injections are currently used, and have been the standard 
for decades in clinical practice for pain relief and control of local 
inflammation in OA. Such practice is still controversial as there is 
fear these injections may promote joint destruction and tissue 
atrophy. Conversely, recent studies in animal models have 
shown that corticosteroid injections can in fact prevent cartilage 
degradation. 
To demonstrate the difference in outcome and rate of cartilage 
degradation among patients with knee OA treated with intra- 
articular steroid injections, 70 patients fulfilling the American 
College of Rheumatology criteria for primary, knee OA were 
randomly chosen to receive intra-articular injections of a steroid 
(40 mg triamcinolone hexacetonide) or a vehicle, at three-month 
intervals, for a prospective period of two years. Patients with a 
standing radiograph showing a joint space width of the knee 
internal compartment of less than 2 mm were excluded. Conven- 
tional treatment (i.e. analgesics and nonsteroidal anti-inflammatory 
drugs [NSAID] except indomethacin) was prescribed according to 
the practitioners' usage and was systematically recorded. The 
radiological progression of joint space narrowing of the injected 
knee over two years was our primary outcome variable. The 
progression is assessed blindly at one and two years of treatment 
• with the validated Buckland-Wright protocol. Clinical evaluation of 
the patients using validated measures (Western Ontario McMaster 
University osteoarthritis index (WOMAC), global assessments with 
visual analog scales, 50-foot walking time) was also conducted 
every three months by blinded investigators. Sixty-eight patients 
completed the study. Baseline characteristics between the two 
groups regarding clinical and anatomical measurements were 
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similar. Although both groups are improving over the two-year 
follow-up period, the results from the clinical measurements of 
efficiency, including the WOMAC pain, stiffness and function, the 
physician global assessment, the range of movement, the 50-foot 
walktime, and analgesic and NSAID consumption favored one 
group. No infection, acute flares of the disease or surgery was 
associated with either treatment group throughout he study. The 
results Of the intra-articular injections on the radiological progres- 
sion of knee OA will be presented. 
Evaluating the anatomical progression of OA is possible with plain 
standardized radiographs. The efficacy of therapeutic interventions 
on the progression of OA may be demonstrated if such interven- 
tions are potent. This clinical trial should address the question of 
whether or not intra-articular steroid injections can prevent the 
progression of knee OA. 
IP009 
EULAR RECOMMENDATIONS FOR THE TREATMENT OF 
KNEE OA 
M. Doherty and M. Dougados ° 
City Hospital, Nottingham, UK and *Hopital Cochin, Paris, France 
Several guidelines have been proposed for the management of 
knee osteoarthritis (OA), including those from the American 
College of Rheumatology (ACR) ~ and the British Society for 
Rheumatology 2. ACR guidelines are currently being updated. 
So far all published guidelines represent consensus statements by 
experts in OA. However, in 1999 a task force of the EULAR 
Standing Committee for Clinical Trials was constituted from 
experts in evidence-based guideline methodology as well as from 
experts in OA research and treatment. 13 European countries 
were represented. The committee determined important clinical 
questions and treatment modalities relating to knee OA manage- 
ment and then undertook a literature review (up to December 
1998). 23 different pharmacological and non-pharmacological 
treatments were reviewed from an initial database of over 
1400studies. Quality scores were undertaken on all studies. 
Wherever possible standardized effect sizes and Numbers 
Needed to Treat (NNT) for 50% and 20% reductions in baseline 
pain were calculated. Recommendations based on such evidence 
were then made with ranking of the strength of the recommenda- 
tions according to the degree of evidence available. A consensus 
approach was employed for evaluation, through serial question- 
naires, of the relative advantages and disadvantages (practicality, 
expense, side effect profile etc.) of the different modalities. The 
preliminary results of the Recommendations were presented at the 
EULAR 2000 Congress in Nice. 
Quality scores for many (especially earlier) studies were poor. 
Effect sizes and NNTs could be calculated for only a minority due 
to lack of required numerical information. 10 issues in the manage- 
ment of knee OA were given ranked recommendations. The need 
for further studies of good quality and appropriate design to 
address important clinical questions was highlighted. A suggested 
research naturally evolved from this evidence-based approach. 
The EULAR 2000 recommendations now require discussion and 
evaluation by different health care professionals. They will require 
reappraisal and updating in the light of new data and changing 
clinical practice. 
References 
1) Hochberg M, et al. Guidelines for the medical management of 
osteoarthritis. Arthritis Rheum 1995;38:1541-6. 
2) Scott DL. Guidelines for the diagnosis, investigation and 
management of osteoarthritis of the hip and knee. J Roy Coil Phys 
London 1993;27:391-6. 
IP010 
TOWARDS STANDARDIZATION OF OSTEOARTHRITIS 
HISTOPATHOLOGY: TERMINOLOGY, TOPOLOGY AND 
TECHNOLOGY 
K. P. H~ Pritzker, K. Ostergaard and D. Salter 
Mount Sinai Hospital, University of Toronto, Toronto, Canada; 
University of Copenhagen, Copenhagen, Denmark; University of 
Edinburgh, Edinburgh, United Kingdom 
A clear understanding of histopathologic events indicative of 
osteoarthritic activity and progression is a prerequisite for devel- 
oping insight into osteoarthritis biology and for devising effective 
therapeutic strategies. Recently, the validity and reproducibility of 
the commonly used histologic histochemical osteoarthritis grading 
system has been questioned, particularly as it does not address 
early disease nor is the grading scale linear. 
Review of the issues concerning standardization of osteoarthritis 
histopathology, reveals the need to standardize nomenclature, 
topologic sample selection and histologic processing. 
Presently, the descriptive terminology of osteoarthritis is imprecise 
with examples of the same term, e.g. fibrillation, used to describe 
different features and different terms, e.g. cleft and fissure to 
describe the same feature. By studying the historic use of terms 
and the consistency of use, a pathway to standardization of 
osteoarthritis histopathology terminology is being determined. 
As joint tissues respond to injury variably in different parts of the 
joint and as imaging/pathology correlation is critical to assessing 
disease progress, topologic sampling standardization of osteo- 
arthritic tissues is essential. Standardization is required not only for 
human joints but also for experimental models of osteoarthritis. 
Ideal samples would demonstrate the range of osteoarthritic 
pathology from least affected to most affected tissues, would 
correlate with in vivo diagnostic images and would be taken at sites 
with fixed relationships to normal topologic landmarks. 
Assessment of osteoarthritis histopathology depends principally on 
assessment by light microscopy of sections stained with cationic 
dyes which demonstrate relative proteoglycan concentrations of 
the extracellular matrix. Standardization is required in fixation, 
decalcification, choice of dye (Toluidine Blue, Safranin-O) and their 
staining procedures. Standard techniques are also required to 
assess chondrocyte function, collagen distribution and other 
features of cartilage composition. 
Standardization of osteoarthritis pathology with respect to 
terminology, topology and technology will contribute not only to 
better quality osteoarthritis research but is likely to provide insights 
into the pathogenesis of osteoarthritis and subtypes. 
IP011 
THE ROLE OF MUSCLE WEAKNESS IN THE 
PATHOGENESIS OF OSTEOARTHRITIS: DOES THE CART 
COME BEFORE THE HORSE? 
M. V. Hurley 
Physiotherapy Division, King's College London, United Kingdom 
Synovial joints are functional units of the neuromuscular skeletal 
system and are composed of intra-articular structures and the 
peri-articular muscles and nerves that cross the joint. Therefore 
muscles and joints are intimately linked and if any component of 
this unit is dysfunctional the joint will be dysfunctional and damage 
may ensue. 
Most research into the aetiology and pathology of osteoarthritis 
(OA) has concentrated on the pathological processes that occur in 
the intra-articular environment, few studies have investigated the 
role of muscle dysfunction in the pathogenesis of OA. 
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Controlled by the higher centres muscles effect and control move- 
ment, act as shock absorbers, help prevent abnormal movement, 
bestow functional stability and are organs of sensory appreciatiop, 
i.e. proprioception. Motor dysfunction decreases the neuro- 
protective mechanisms leading to excessive joint movement, 
instability and poorly controlled joint loading and stress. This may 
lead to the pathological and clinical features indicative of OA. 
Although it is normally assumed that joint damage precedes 
muscle weakness this assumption has not been val(dated. Indirect 
evidence can be used to formulate the argument that muscle 
sensorimotor dysfunction may be an important factor in the patho- 
genesis of articular damage; there is a poor association between 
radiologicat changes and muscle weakness, pain and disability; 
muscle weakness may precede and predict future joint damage; 
age-related decrease in muscle function might cause the age- 
related increase in the incidence of OA; muscle dysfunction alters 
gait that may cause joint damage and pain; injury causes muscle 
weakness that may pre-dispose the limb to joint damage; muscle 
fatigue decreases the'neuroprotective mechanism, impairing the 
shock absorbing capacity of muscle and increasing the risk of joint 
damage. 
There is a need to appreciate the complex inter-relationship 
between muscle sensorimotor dysfunction, joint damage and 
disability in OA. 
This might be good news because muscle is an extremely "plastic" 
tissue and the component of synovial joints which can be most 
readily altered by us. This give us an important strategy in the 
management of OA since maintaining well-conditioned muscles 
may prevent or delay the onset of OA and rehabilitation that 
reverses muscle sensorimotor dysfunction may decrease pain, 
disability and retard the progression of OA. More clinically 
practicable rehabilitation regimes need to be devised that could be 
implemented in the community, if the management of this 
chronic, prevalent condition is to be managed effectively and 
cost-effectively. 
IP012 
THE NEUROMUSCULAR PROTECTION OF SYNOVlAL 
JOINTS 
Brian L. O'Connor 
Formerly - Department of Anatomy, Indiana University School of 
Medicine 
The neuromuscular system regulates joint use by determining if, 
when and how much movement and loading occur. Thus, this 
system is the primary determinate of the joints "mechanical 
environment" (the total spectrum of forces acting on articular and 
periarticular tissues). If the mechanical environment is compatible 
with the well-being of joint tissues, healthy joints may remain 
healthy and diseased joints may respond favorably to treatment. If 
the mechanical environment is not compatible with joint health, a 
normal joint will develop traumatic osteoarthritis (OA), and therapy 
of a diseased joint will fail. How might neuromuscular mechanisms 
control the mechanical environment? 
In dogs with stable joints, extensive unilateral hind limb deafferen- 
tation by L4-$1 dorsal root ganglionectomy (DRG) did notproduce 
ipsilateral knee OA in active animals for 72 weeks after surgery. 
Moreover, the dogs bore weight normally on their deafferented 
limb, and the range of joint excursion was nearly normal. 
The absence of OA in these dogs indicates that the mechanical 
environment that protected the stable, healthy knee did not depend 
upon ipsilateral sensation, and nearly normal use of these joints 
shows that protection did not occur because the dogs immobilized 
or unloaded the deafferented knee. 
In neurologically intact dogs who had transection of the anterior 
cruciate ligament (ACLT), knee OA was mild 72 weeks after 
surgery. But, when DRG preceded ACLT, OA was very severe 72 
weeks after ACLT. (Limb loading was decreased in both groups.) 
Thus, ipsilateral sensory nerves, although not important in protect- 
ing stable joints from OA, were very important in protecting acutely 
unstable knees from severe OA. 
This suggests that 2 separate sets of neuromuscular protective 
mechanisms exist. One set, not dependent on ipsilateral sen- 
sation, protects stable joints from the initiation of OA. The second 
set, highly dependent on ipsilateral sensation, protects acutely 
unstable joints from severe, rapidly-developing OA, but not from 
mild, slowly-developing OA. 
Finally, when DRG was performed 52 weeks after ACLT, and the 
dogs killed 20 weeks thereafter (72 weeks after ACLT), OA was not 
more severe than OA in clogs with intact sensory nerves who were 
sacrificed 72 weeks after ACLT. Moreover, after undergoing DRG 
52 weeks after ACLT, loading of the ipsilateral limb returned 
to (lower) pre-DRG (post-ACLT) levels, rather than to (higher) 
baseline (pre-ACLT)levels. 
Why might ipsilateral sensory nerves be critical for protecting the 
acutely unstable knee from developing severe OA, but not for 
protecting healthy joints from developing OA, or protecting 
chronically unstable knees with mild OA from developing severe 
OA? 
Protection of the deafferented stable knee likely occurred as an 
inevitable by-product of the normal joint being used normally, with 
central pattern generators (CPGs - the basis of movement) being 
appropriately modulated by sensation from other limbs, eyes, 
vestibular system, etc. In the acutely unstable but afferented limb, 
sensations of pain and instability likely protected the knee from 
severe OA by modifying CPGs to reduce trauma as the dogs 
balanced "least aversive" against "normal" joint use. OA likely was 
severe in the acutely unstable, deafferented limb because the 
central nervous system could neither accurately characterize nor 
assess the nature of instability, and thereby responded inappropri- 
ately to it. Presumably, in the chronically unstable knees that were 
deafferented 52 weeks after ACLT (and developed mild OA), the 
dogs had practiced the compromises between "least aversive" and 
"normal" joint use sufficiently to reprogram the CPGs such that 
neuromuscular protection (from severe OA) could again occur (as 
in the case of normal knees) without CPGs requiring ipsilateral 
sensation. 
Clearly, neuromuscular mechanisms are profoundly important in 
the protection of both stable and unstable joints, and cannot be 
ignored if successful treatments for OA are to be devised. 
IP013 
EXERCISE IN THE TREATMENT OF OSTEOARTHRITIS (OA) 
M. Minor 
University of Missouri, Columbia, MO, USA 
Successful treatment of OA reduces pain and disability, minimizes 
disease progression and prevents unnecessary secondary condi- 
tions. Commonly recommended interventions include drugs and 
physical modalities to relieve pain, education to promote self- 
management skills, surgery to replace involved joints, and 
exercise. There is mounting evidence for the safety and effective- 
.ness of exercise as a client-centered intervention for OA of the hip 
and knee. Positive results from a variety of aerobic and neuro- 
musculoskeletal conditioning interventions have been reported 
from controlled trials and in systematic reviews. Types of aerobic 
exercise studied include pool exercise, walking, stationary bicycle, 
and aerobic dance. Neuromuscular training has used isometric, 
isotonic and isokinetic methods in joint specific and general 
training programs in both supervised and home settings. Benefits 
include improved neuromuscular function (strength, endurance, 
proprioception), improved joint range of motion, decreased pain, 
improved cardiovascular fitness, decreased disability, improved 
function, increased levels of daily physical and social activity as 
well as improved psychological status. Beneficial effects of the 
various interventions range from small to great in both objective 
and subjective measures; and there is no evidence that disease is 
worsened or signs or symptoms increased by regular exercise 
performed at conditional evels. In addition to the clinical evidence 
supporting exercise treatment, there also is evidence of the 
beneficial effects of exercise on joint physiology. In addition to the 
well-recognized need for regular motion and intermittent weight 
bearing to maintain cartilage and bone integrity, there is emerging 
information that dynamic exercise also has a positive effect on 
synovial blood flow and intra-articular pressure. Appreciation of the 
multiple benefits of physical activity and exercise in OA stems from 
an understanding that disability in hip and knee OA is clearly 
associated with lower extremity muscle weakness, diminished joint 
range of motion, pain, inactivity and de-conditioning; and that 
appropriately performed exercise is an effective and inexpensive 
therapy to manage these problems. Recommendations for 
adequate levels of physical activity to promote general health and 
guidelines for attaining cardiovascular and musculoskeletal fitness 
appear to be feasible for many people with OA. The specific 
benefits derived from exercise depend upon the selected exercise 
mode, frequency, intensity and duration of the exercise stimulus in 
conjunction with the status and response of the targeted organ 
systems. 
IP014 
GENE THERAPY 
C. W. Mcllwraith and D. D. Frisbie 
Colorado State University, Fort Collins, Colorado 80523 
Osteoarthritis (OA) is now recognized as the result of biological 
processes and the treatment of OA should use biological 
principles. Biologically based therapies for OA can be grouped into 
two complementary approaches that are aimed at inhibiting 
cartilage breakdown or enhancing cartilage synthesis. Examples of 
the former might include the use of IL-1 receptor antagonist, 
IL-1 soluble receptors, TNF soluble receptors, or MMP inhibitors. 
Examples of the latter might include the provision of growth factors 
such as IGFs, GMPs or TGF betas or the antagonism of suppress- 
ing cytokines with IL-1 RA, IL-1 sR, TNF sR. The IL-1 system has 
been centrally linked to pathologic change associated with OA and 
it is known that binding of the IL-1 RA protein to IL-1 receptors 
serve to block the binding of the IL-1 alpha and beta ligands. A 
project will be described that assessed the ability to deliver 
transgene to the joint of horses using gene transfer that produced 
overproduction of IL-1 RA and inhibited articular cartilage 
degradation in an experimental model of OA in the exercising 
horse. 
Using the gene sequence for equine IL-1 RA previously defined in 
our laboratory, an adenoviral vector (Ad-EqlL-1Ra) was con- 
structed that was capable of equine IL-1 RA transgene expression. 
The vector was tested in vitro to ensure its ability to both transduce 
equine synoviocytes without cytotoxic effects and produce a 
biologically active IL-1 RA molecule. The dose titration of the 
vector was conducted in vivo in the equine intercarpal joint to 
ascertain the concentration of vector that produced the highest 
transgene expression for the longest period of time without 
significant deleterious effects. This work suggested a vector con- 
centration of 20 x 10 l° particles per joint as optimal. Using an 
experimental model of equine OA, the ability of intra-articular (IA) 
administration of Ad-EqlL-1Ra to inhibit pathologic change was 
evaluated. An approximately 28-day effect of up-regulation of 
IL-1Ra expression through a single injection of Ad-EqlL-1Ra 
was demonstrated. Using a single intra-articular injection of 
Ad-EqlL-1Ra 14 days after the induction of the OA model in the 
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horse, significant improvement in clinical parameters of lameness 
and joint effusion, beneficial effects in histologic parameters 
measured from the synovial membrane as well as attenuation of 
gross, histologic and histochemical changes in the articular 
cartilage was demonstrated. The study provided proof of principle 
that gene therapy using a potentially anti-arthritic gene sequence 
is possible and efficacious in the horse. This is the first study to 
demonstrate a clinical improvement in OA as a result of gene 
therapy. The duration of transgene expression was also 
significantly longer than found in other studies using in vivo IL-1 RA 
gene transfer with adenoviral systems and it may be associated 
with this being the first study involving transfer of the gene 
sequence from the same species into the patient (and possibly a 
decreased immune response), Work is now being undertaken 
evaluating the use of combination gene therapy protocol using 
both IL-1RA and IGF-1 gene transfer using the same adenoviral 
vector in equine joints with established articular cartilage defects. 
IP015 
MECHANISMS AND IMPLICATIONS OF CARTILAGE REPAIR 
EX-VIVO 
G. A. Homandberg 
Rush Medical College at Rush-Presbyterian-St. Luke's Med. Ctr, 
Chicago, IL 60612, USA 
In order to better understand the linkage of cartilage matrix 
damage to attempted repair, we have utilized an ex vivo cartilage 
damage model and an animal model in which fragments (Fn-f) of 
the cartilage matrix protein, fibronectin (Fn), are added to cultured 
cartilage or injected into rabbit knee joints. In this model, the Fn-fs 
alter the normal communication between Fn and the alphasbeta 1
receptor, leading to short term upregulation of catabolic cytokines 
and matrix metalloproteinases and short term suppression of 
matrix protein synthesis. After this catabolic pulse, anabolic 
responses of the cartilage begin to predominate as proteoglycan 
(PG) synthesis increases to above normal levels. In contrast, with 
a continuous insult with a low Fn-f concentration or a short 
exposure with a high Fn-f concentration, this anabolic response 
occurs immediately, followed much later by cartilage matrix 
damage. Thus, the anabolic response appears to be operating 
continuously but can be masked by an elevated catabolic pathway 
initiated by high Fn-f concentrations. This anabolic response of 
enhanced PG synthesis can be mimicked by addition of trypsin or 
MMP-3 to cultured cartilage, suggesting that the Fn-f affect 
requires protease activity. We hypothesize that the proteases are 
liberating IGF-1 from binding protein complexes. With multiple 
short exposures of cartilage to the Fn-fs which total less than the 
period required for maximal cytokine expression, the cartilage is 
made more resistant o damage, suggesting that there is a minimal 
length of time that dictates whether cartilage becomes damaged or 
conditioned. Once the Fn-fs do initiate severe matrix loss in mature 
cartilage, the PG is not restored even after the Fn-fs are removed. 
This appears to be due to cytokine and MMP upregulation that 
persists after the Fn-fs are removed. Since catabolic activities 
remain elevated in cartilage attempting repair, it is reasonable to 
expect that agents that can block the initial Fn-f damage may be 
useful for repairing damage in the absence of Fn-f. Indeed, 
anabolic factors such as IGF-1 or OP-1 not only block Fn-f 
mediated damage, but also enhance reparative responses. 
Further, anti-catabolic agents such as MMP inhibitors, cytokine- 
blocking anti-oxidants and Fn receptor antagonists that block Fn-f 
damage, also help restore lost PG. In contrast to the above results 
with mature cartilage, cartilage from adolescent humans or from 
adolescent animals with higher rates of PG synthesis, either are 
not damaged or if damaged, can restore PG spontaneously. These 
above data collectively suggest that other types of agents, other 
than Fn-fs, that might mildly stimulate matrix degradation, might 
also enhance reparative processes. An example is high molecular 
weight hyaluronic acid, which slightly enhances matrix degradation 
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and restores PG in damaged cartilage. In summary, studies of our 
model show (1) that severe cartilage matrix damage leads to 
subsequently enhanced anabolic activities as in a repair response; 
(2) that the attempted repair may initially fail because the damag- 
ing pathway may "coast" after the insult is removed; (3) that a low 
grade of cartilage matrix damage may normally enhance anabolic 
responses and make cartilage more resistant to further damage; 
and (4) that agents that block cartilage matrix damage should also 
facilitate repair. 
Supported by the NIAMSD SCOR Grant AR39239-03, Glaxo 
Wellcome, Seikagaku Corp. and the Dr Ralph and Marian C. Falk 
Medical Research Trust Fund. 
IP016  
AGGRECANASE: A NOVEL METALLOPROTEASE TARGET 
FOR INHIBITION OF CARTILAGE DEGRADATION 
Elizabeth Arner °. Midky Tortorellal-, Michael Pratta, James 
Trzaskos, Ronald Magolda$ and Timothy Burn 
DuPont Pharmaceuticals Company, Inflammatory Diseases 
Research, Experimental Station, Wilmington, DE 19880-0400 
The degradation of aggrecan is a key factor in the gradual erosion 
of articular cartilage that leads to a loss of joint function in arthritis. 
Matrix metalloproteinases (MMPs) have been shown to cleave 
in vitro at the Asn341-342Phe bond of aggrecan. However, 
aggrecanase appears to be responsible for aggrecan cleavage at 
the Glu373-374Ala bond to release the large C-terminal fragments 
that have been identified in synovial fluids from patients with 
arthritis and joint injury. We purified two aggrecanase proteins, 
aggrecanase-1 (ADAMTS-4) and aggrecanase-2 (ADAMTS-5) 
from bovine nasal cartilage conditioned media and cloned and 
expressed the human orthologs of these novel proteins. These 
aggrecanases are secreted proteins that are members of the A 
Disintegdn and Metalloproteinase with Thrombospondin motifs 
(ADAMTS) family. Using recombinant human aggrecanase-1, we 
have demonstrated that in addition to cleavage at the Glu 373-374 
Ala bond, aggrecanase cleaves at four sites within the chondro- 
itin-sulfate rich region of the aggrecan core protein, between G2 
and G3. Importantly, we showed that aggrecanase cleaves prefer- 
entially within the C-terminal region of aggrecan, prior to the 
cleavage within the interglobular domain (IGD) at the Glu 373-374 
Ala bond to produce fragments with the N-terminus ARGS. 
Neoepitope antibodies to fragments produced by cleavage at each 
of these sites were used to examine aggrecan fragment formation 
in tissue and medium from bovine articular cartilage cultures. Our 
data demonstrate that these fragments are produced in the same 
temporal relationship during IL-1 stimulated cartilage degradation 
as upon cleavage of isolated aggrecan with aggrecanase. As 
expected, the generation of all of these cleavages was inhibited by 
an aggrecanase inhibitor, and not by a broad MMP inhibitor that 
lacks the ability to inhibit aggrecanase. These data indicate that 
aggrecan cleavage in situ, in cartilage explant cultures, occurs at 
the same sites and in the same temporal sequence as that 
produced by cleavage of aggrecan by recombinant aggrecanase. 
Other studies characterizing the aggrecanase enzymes will be 
discussed. 
Current addresses: "Pharmacia, 4901 Searle Parkway, J-200A, 
Skokie, IL 60077; 1"The Kennedy Institute of Rheumatology, 1 
Aspenlea Road, Hammersmith, London W6 8LH, UK; :l:Boeringer 
Ingelheim, R&D Center, P.O. Box 368, 900 Ridgebury, Ridgefield, 
CT 06877. 
IP017  
WHO GETS OSTEOARTHRITIS 
R. Hirsch 
National Center for Health Statistics, Hyattsville, MD, USA 
Age, gender and race/ethnicity are strong indicators of individuals 
at risk for osteoarthritis (OA). There is a striking and consistent 
correlation between OA and increasing age in all epidemiologic 
studies. OA is uncommon in individuals less than 30 years of age, 
with the earliest onset seen in the first metatarsophalangeal joint 
by age 25 years. By age 45 years, the distal interphalangeal joints 
and knees are often affected. Not until age 55-60 years do the 
proximal interphalangeal, first carpometacarpal and hips become 
significantly involved. Prevalence of hand OA exceeds 80% by age 
75 years, but several studies have shown a plateau effect after age 
75 years for hand and knee OA. 
Until the age of about 45 years, OA prevalence is slightly higher in 
men than women, but equal between the ages of 45-55 years. 
After the age of 55 years, hand and knee OA are more common in 
women, with a continued widening of the gender prevalence 
differences with increasing age. Polyarticular OA, inflammatory 
OA, and disease severity are also more frequent in women. 
However, most population studies show a higher prevalence of hip 
OA in men. 
Studies comparing disease prevalence across populations or 
subgroups are conducted to gain insights about etiology. Differ- 
ences in OA prevalence or patterns may be due to genetics or risk 
factor distribution. However they may also be due to differences in 
technique, inter-reader variations, and criteria for disease 
definition. These factors limit the ability to directly compare findings 
across studies. 
White populations of Europe and the United States have similar 
frequencies of hand, knee and hip OA, and in general have the 
highest disease frequency compared to other race/ethnicities. 
Although hand OA is common to all populations studied, 
Heberden's nodes are rare in African, Caribbean and United States 
black populations, and are less common in Native Americans than 
whites. In several studies, knee OA has been found to be more 
common in blacks than whites in the same region, however other 
studies have shown comparable frequencies of knee OA between 
racial/ethnic groups. Population-based studies have demonstrated 
higher frequencies of knee OA in overweight versus non- 
overweight individuals. Hip OA frequency shows the most disparity 
across racial/ethnic groups. It is most common in white popula- 
tions, less so in blacks and Native Americans, and rare in the East 
Asian populations studied. Patterns of joint involvement can also 
differ between populations. African blacks have a pauci-articular 
disease pattern, whereas Caribbean blacks manifest polyarticular 
involvement as commonly as whites. There is a paucity of 
epidemiologic data on other race/ethnicity groups, including 
Hispanics, Pacific Islanders, and Central, South and West Asian 
populations. 
